Day One Biopharmaceuticals (DAWN) Competitors $7.62 -0.16 (-2.06%) Closing price 05/1/2025 04:00 PM EasternExtended Trading$7.38 -0.24 (-3.20%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DAWN vs. MOR, SRRK, PTGX, CRNX, SWTX, OGN, CPRX, VKTX, XENE, and MLTXShould you be buying Day One Biopharmaceuticals stock or one of its competitors? The main competitors of Day One Biopharmaceuticals include MorphoSys (MOR), Scholar Rock (SRRK), Protagonist Therapeutics (PTGX), Crinetics Pharmaceuticals (CRNX), SpringWorks Therapeutics (SWTX), Organon & Co. (OGN), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Xenon Pharmaceuticals (XENE), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Day One Biopharmaceuticals vs. MorphoSys Scholar Rock Protagonist Therapeutics Crinetics Pharmaceuticals SpringWorks Therapeutics Organon & Co. Catalyst Pharmaceuticals Viking Therapeutics Xenon Pharmaceuticals MoonLake Immunotherapeutics MorphoSys (NASDAQ:MOR) and Day One Biopharmaceuticals (NASDAQ:DAWN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends, analyst recommendations and community ranking. Does the MarketBeat Community favor MOR or DAWN? Day One Biopharmaceuticals received 29 more outperform votes than MorphoSys when rated by MarketBeat users. Likewise, 70.13% of users gave Day One Biopharmaceuticals an outperform vote while only 38.46% of users gave MorphoSys an outperform vote. CompanyUnderperformOutperformMorphoSysOutperform Votes2538.46% Underperform Votes4061.54% Day One BiopharmaceuticalsOutperform Votes5470.13% Underperform Votes2329.87% Is MOR or DAWN more profitable? Day One Biopharmaceuticals has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Day One Biopharmaceuticals' return on equity of -22.40% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets MorphoSys-226.79% -694.31% -22.55% Day One Biopharmaceuticals N/A -22.40%-19.79% Do analysts rate MOR or DAWN? Day One Biopharmaceuticals has a consensus price target of $32.29, suggesting a potential upside of 323.70%. Given Day One Biopharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Day One Biopharmaceuticals is more favorable than MorphoSys.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Day One Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media prefer MOR or DAWN? In the previous week, Day One Biopharmaceuticals had 9 more articles in the media than MorphoSys. MarketBeat recorded 9 mentions for Day One Biopharmaceuticals and 0 mentions for MorphoSys. Day One Biopharmaceuticals' average media sentiment score of 0.52 beat MorphoSys' score of 0.00 indicating that Day One Biopharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment MorphoSys Neutral Day One Biopharmaceuticals Positive Which has higher valuation & earnings, MOR or DAWN? Day One Biopharmaceuticals has lower revenue, but higher earnings than MorphoSys. Day One Biopharmaceuticals is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMorphoSys$238.28M11.99-$205.35M-$3.48-5.45Day One Biopharmaceuticals$131.16M5.89-$188.92M-$1.08-7.06 Do institutionals and insiders believe in MOR or DAWN? 18.4% of MorphoSys shares are owned by institutional investors. Comparatively, 87.9% of Day One Biopharmaceuticals shares are owned by institutional investors. 0.1% of MorphoSys shares are owned by insiders. Comparatively, 6.2% of Day One Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, MOR or DAWN? MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Day One Biopharmaceuticals has a beta of -1.24, suggesting that its share price is 224% less volatile than the S&P 500. SummaryDay One Biopharmaceuticals beats MorphoSys on 15 of the 19 factors compared between the two stocks. Get Day One Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for DAWN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DAWN vs. The Competition Export to ExcelMetricDay One BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$772.32M$6.84B$5.53B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-7.407.3222.5118.54Price / Sales5.89241.49397.62103.34Price / CashN/A65.8538.1834.62Price / Book1.916.486.734.25Net Income-$188.92M$143.41M$3.22B$248.18M7 Day Performance-3.54%2.30%1.58%1.25%1 Month Performance0.13%7.14%4.05%3.76%1 Year Performance-56.92%-2.61%15.75%5.28% Day One Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAWNDay One Biopharmaceuticals2.4635 of 5 stars$7.62-2.1%$32.29+323.7%-56.9%$772.32M$131.16M-7.4060Upcoming EarningsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SRRKScholar Rock4.0472 of 5 stars$29.81-3.1%$42.67+43.1%+119.0%$2.83B$33.19M-12.69140Upcoming EarningsInsider TradeNews CoveragePositive NewsPTGXProtagonist Therapeutics3.4659 of 5 stars$45.80-1.0%$65.44+42.9%+76.0%$2.81B$434.43M17.22120Upcoming EarningsPositive NewsCRNXCrinetics Pharmaceuticals3.6538 of 5 stars$30.15-0.9%$73.00+142.1%-25.6%$2.81B$1.04M-8.08210Upcoming EarningsNews CoveragePositive NewsSWTXSpringWorks Therapeutics1.941 of 5 stars$37.06-2.3%$73.20+97.5%-1.3%$2.78B$191.59M-10.65230Analyst ForecastOGNOrganon & Co.4.715 of 5 stars$10.67-4.0%$20.60+93.1%-49.9%$2.75B$6.40B3.2010,000Earnings ReportOptions VolumeNews CoverageGap DownCPRXCatalyst Pharmaceuticals4.6852 of 5 stars$22.02-2.2%$32.29+46.6%+59.7%$2.69B$491.73M18.6680Upcoming EarningsPositive NewsVKTXViking Therapeutics4.4923 of 5 stars$23.72-0.9%$89.75+278.4%-62.6%$2.66BN/A-23.7220Analyst UpgradeOptions VolumeAnalyst RevisionXENEXenon Pharmaceuticals2.59 of 5 stars$34.70-1.2%$56.78+63.6%-10.4%$2.66B$9.43M-12.30210Upcoming EarningsOptions VolumePositive NewsMLTXMoonLake Immunotherapeutics1.548 of 5 stars$40.00+4.4%$80.50+101.3%-3.3%$2.56BN/A-31.012Upcoming EarningsAnalyst Forecast Related Companies and Tools Related Companies MorphoSys Competitors Scholar Rock Competitors Protagonist Therapeutics Competitors Crinetics Pharmaceuticals Competitors SpringWorks Therapeutics Competitors Organon & Co. Competitors Catalyst Pharmaceuticals Competitors Viking Therapeutics Competitors Xenon Pharmaceuticals Competitors MoonLake Immunotherapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DAWN) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Day One Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Day One Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DAWN Stock Free DAWN Stock Alerts